Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 352-360

  Thike, Aye Aye ^a,b,c   Chong, Luke Yong Zheng ^a,b,c   Cheok, Poh Yian ^a   Li, Hui Hua ^b   Yip, George Wai Cheong ^b   Bay, Boon Huat ^c   Tse, Gary Man Kit ^a,b,c   Iqbal, Jabed ^a,b,c   Tan, Puay Hoon ^a,b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Androgen receptor; Outcome; Triple negative and basal like breast cancer

Indexed keywords

34 BETA E12; ANDROGEN RECEPTOR; BIOTIN; CYTOKERATIN 14; EPIDERMAL GROWTH FACTOR RECEPTOR; STREPTAVIDIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANDROGEN; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896710159     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.145     Document Type: Article

References (46)

1. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23: 7350-7360.
2. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10: 5367-5374.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13: 4429-4434.
4. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11: 5678-5685.
5. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
6. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospect. Ther Adv Med Oncol 2013;5: 169-181.
7. Yu YL, Chou RH, Liang JH, et al. Targeting the EGFR/ PCNA signaling suppresses tumor growth of triplenegative breast cancer cells with cell-penetrating PCNA peptides. PLoS One 8e61362.
8. Brunello A, Borgato L, Basso U, et al. Targeted approaches to triple negative breast cancer: current practice and future directions. Curr Med Chem 2013; 20: 605-612.
9. Moe RE, Anderson BO. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 2007;95: 437-439.
10. Higgins MJ, Wolff AC. The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat 2010;124: 619-621.
11. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010;16: 62-65.
12. Yeh S, Hu YC, Wang PH, et al. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 2003;198: 1899-1908.
13. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002; 80: 175-189.
14. Li S, Han B, Liu G, et al. Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem 2010;58: 509-515.
15. Doane AS, Danso M, Lal P, et al. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25: 3994-4008.
16. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52: 459-467.
17. Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20: 119-131.
18. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120: 725-731.
19. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15: 2472-2478.
20. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11: 155-168.
21. Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triplenegative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010;23: 123-133.
22. Thike AA, Iqbal J, Cheok PY, et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010;34: 956-964.
23. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32: 1560-1565.
24. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
25. De Launoit Y, Dauvois S, Dufour M, et al. Inhibition of cell cycle kinetics and proliferation by the androgen 5- dihydrotestosterone and antiestrogen N,n-butyl-Nmethyl- 11-[16-chloro-3,17-dihydroxy-estra-1,3,5-(10) triene-7yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991;51: 2797-2802.
26. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg 2007;31: 1041-1046.
27. Kemppainen JA, Langley E, Wong CI, et al. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 1999;13: 440-454.
28. Birrell SN, Butler LM, Harris JM, et al. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 2007;21: 2285-2293.
29. Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptornegative tumors with apocrine differentiation. Mod Pathol 2010;23: 205-212.
30. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010; 21: 488-492.
31. Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009;69: 6131-6140.
32. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1999;32: 1560-1565.
33. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 2001;106: 111-125.
34. Xie B, Tsao SW, Wong YC. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis 1999;20: 1597-1606.
35. Park JJ, Irvine RA, Buchanan G, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000;60: 5946-5949.
36. Bryan RM, Mercer RJ, Bennett RC, et al. Androgen receptors in breast cancer. Cancer 1984;54: 2436-2440.
37. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170: 31-35.
38. Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011;24: 924-931.
39. Mossler JA, Barton TK, Brinkhous AD, et al. Apocrine differentiation in human mammary carcinoma. Cancer 1980;46: 2463-2471.
40. Miller WR, Shivas AA, Franchimont P, et al. Breast gross cystic disease protein 15 in human breast cancer in culture. Eur J Cancer Clin Oncol 1988;24: 223-228.
41. O'Malley F, Eusebi V, Lakhani SR. Carcinomas with apocrine differentiation; In: Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds)., WHO Classification of Tumours of the Breast 4th edn. IARC Press: Lyon, France; 2012, pp 53-54.
42. Bundred NJ, Walker RA, Everington D, et al. Is apocrine differentiation in breast carcinoma of prognostic significance? Br J Cancer 1990;62: 113-117.
43. Karamanakos P, Mitsiades CS, Lembessis P, et al. Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Res 2004;24: 1077-1081.
44. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Fut Oncol 2008;4: 15-21.
45. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg 2004;139: 50-54.
46. Suzuki T, Miki Y, Akahira J, et al. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocr J 2008;55: 455-463.